NCT06386211View on ClinicalTrials.gov

Bioavailability Study of Magne-B6 New Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 3, 2024

Primary Completion Date

August 24, 2024

Study Completion Date

August 24, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

MAGNE-B6 Oral Solution

Oral solution.

DRUG

MAGNE-B6 New Formulation Tablet

New formulation tablet.

Trial Locations (1)

38039

Erciyes Universitesi Hakan Cetinsaya Iyi Klinik Uygulama ve Araştırma Merkezi Erciyes Universitesi Kampusu, Kayseri

All Listed Sponsors
lead

Opella Healthcare Group SAS, a Sanofi Company

INDUSTRY

NCT06386211 - Bioavailability Study of Magne-B6 New Formulation | Biotech Hunter | Biotech Hunter